natureresearch

| Corresponding author(s): | Stephen Dalton |
|----------------------------|----------------|
| Last updated by author(s): | Jan 30, 2020 |

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

| Statistics | | |
|--|--|--|
| For all statistical analys | es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. | |
| n/a Confirmed | | |
| The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement | | |
| A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly | | |
| The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section. | | |
| A description of all covariates tested | | |
| A description | of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons | |
| | ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) | |
| | thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted is exact values whenever suitable. | |
| For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings | | |
| For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes | | |
| Estimates of e | effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated | |
| 1 | Our web collection on <u>statistics for biologists</u> contains articles on many of the points above. | |
| Software and o | code | |
| | ut availability of computer code | |
| Data collection | No software was used. | |
| Data analysis | Reads were mapped to the human genome (hg19) by STAR v2.5.3a using default setting and read counts were obtained in STAR quant-mode. Gene expression analysis was preformed using limma, Glimma and EdgeR in R Studio | |
| | om algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. | |
| Data | | |
| Accession codes, unA list of figures that | ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability | |
| The RNA-seq data describ | ped in this report has been deposited in the Gene Expression Omnibus under the ID code GSE125331. | |
| Field-speci | fic reporting | |
| Please select the one b | elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection. | |
| X Life sciences | Behavioural & social sciences Ecological, evolutionary & environmental sciences | |

Life sciences study design

| All studies must dis | close on these points even when the disclosure is negative. | |
|----------------------|---|--|
| Sample size | A sample size of n=3 (or more) was used with independent replicates for cell culture experiments. This number of independent replicates is sufficient to determine if the P<0.05, to provide sufficient statistical significance. For statistical significance of mice experiments n=4 (or more), per group was chosen. | |
| Data exclusions | No data was excluded from the study. | |
| Replication | All experiments were replicated by 2 individuals, working independently. | |
| Randomization | For cell samples and mice samples, replicates were randomly selected for control or experimental groups. | |

Blinding Blinding was not performed during the data collection of the experiments. However, as data analysis and statistical significance was not

determined until after the data collection, blinding would would have no impact on the studies performed.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods | |
|----------------------------------|---------------------------|--|
| n/a Involved in the study | n/a Involved in the study | |
| X Antibodies | X ChiP-seq | |
| Eukaryotic cell lines | Flow cytometry | |
| x Palaeontology | MRI-based neuroimaging | |
| Animals and other organisms | · | |
| Human research participants | | |
| X Clinical data | | |

Antibodies

Antibodies used

UCP-1 (Abcam, Ab10983), Perilipin-1 (Cell Signaling Technology, D1D8), CD73-BV421 (BD Biosciences, 562431), CD105-BV421 (BD Biosciences, 563920), IgG1 Isotype-BV421 (BD Biosciences, 562438), CD45-PE (BD Biosciences, 555483), IgG1 Isotype-PE (BD Biosciences, 555749), CD34-PE (R&D Systems, FAB7227P), CD90-APC (eBiosciences, 17-0909-42), UCP1 (Abcam, Ab10983), p-HSLS660 (Cell Signaling, #4126), HSL (Cell Signaling, #4107), p-CREBS133 (Cell Signaling, #9191), p-P38MAPKT180/Y182 (Cell Signaling, #9216), P38MAPK (Cell Signaling, #9212), and Cofillin (Santa Cruz, sc-376476 HRP), anti-rabbit-HRP (Dako, P0448), anti-mouse HRP (Dako, P0260)

Validation

Each antibody was purchased from a commercial vendor, as indicated. Each vendor provided a data-sheet for their antibody, confirming the utility for the antibody in the application used in this study.

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

ADSC cell lines were purchased (ThermoFisher, cat no: R7788115, Lot#: 1001001 and Lot #1001002; ATCC, ASC52telo, cat no: ATCC SCRC-4000; Lonza, cat no: 5006, Lots: 0000543947, 18TL215666; cat no: PT-5008, Lots: 1F4521, 1F4619).

Authentication

ADSC lines were authenticated based on presence/absence of cell surface markers CD73, CD105, CD45, CD34 and CD90

Mycoplasma contamination

All cell lines were confirmed to be negative by mycoplasma testing.

No commonly misidentified lines (See | CLAC register)

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals NOD/SCID mice (NOD/ShiLtSz genetic background, Jackson Laboratory, stock no. 001303) were 12-week old females for indirect calorimetry or 6-8 week old male for blood-glucose studies.

Wild animals Study did not involve wild animals.

Field-collected samples Study did not involve samples collected from the field.

Ethics oversight

Animal experiments were performed following IACUC guidelines at the University of Georgia accredited through AAALAC international. This was in compliance with Public Health Service policy through NIH Office of Laboratory Animal Welfare and

USDA Animal Welfare Act and Regulations.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- | All plots are contour plots with outliers or pseudocolor plots.
- 🗶 A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

ADSCs were collected by first washing cells in PBS, and treating cells with Accutase for 5-10 minutes at room temperture to develop a single-cell suspension. Cells were counted and washed, and aliquoted 0.5 million cells/tube/antibody. Antibody was

develop a single-cell suspension. Cells were counted and washed, and aliquoted 0.5 million cells/tube/antibody. Antibody was added to the cells, and incubated at 30 min (or as indicated by antibody vendor work-sheet). Cells were pelleted, washed, and

used for analysis.

Instrument Beckman Coulter CyAn

Software FlowJo7 was used to analyze the flow cytometry data.

Cell population abundance Cells were not sorted and only used for analysis. Following analysis, cells were discarded.

Gating strategy Cells were only gated on FSC/SSC and no further gating strategy was used.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.